Literature DB >> 29394993

The Value of Prognostic Factors for Survival in Synchronous Multifocal Lung Cancer: A Retrospective Analysis of 164 Patients.

Jinghuan Lv1, Donglin Zhu2, Xiaotong Wang3, Qin Shen3, Qiu Rao3, Xiaojun Zhou4.   

Abstract

BACKGROUND: We reviewed patients treated for synchronous multifocal lung cancers (SMLCs) to analyze outcomes and evaluate valuable prognostic factors.
METHODS: From January 2010 to June 2016, 3,031 patients underwent lung cancer resection at Jinling Hospital and Suzhou Hospital affiliated to Nanjing Medical University, and 164 (5.4%) had SMLC. The Kaplan-Meier method was used for survival analysis, and a multivariable Cox proportional hazards regression model was used for identification of independent survival predictors.
RESULTS: The overall survival and progression-free survival rates with SMLC were 72.6% and 61.0%, respectively. A statistically significant difference existed for overall survival and progression-free survival between synchronous multiple primary lung cancer and intrapulmonary metastases according to Martini criteria. There was no statistical difference among the subgroups categorized by the TNM classification. Furthermore, small tumor size showed a benefit for overall survival and progression-free survival. Patients whose tumors were 0.8 cm or smaller had a 5-year survival rate of 100%. Tumor size, lymphatic metastases, and histologic differentiation were identified by univariate and multivariate regression analysis as independent survival predictors.
CONCLUSIONS: Survival of patients with SMLC is strongly correlated with the tumor size, differentiation, and lymphatic metastases but not with clinical TNM stage. The Martini criteria based on histologic subtyping has certain predictive value to survival. In comparison, tumor size is of greater value for prognosis. Both of the criteria above are much better than the TNM classification. The 5-year survival rate of 100% in patients with tumors sized 0.8 cm or smaller is extremely valuable for predicting survival after surgical resection.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29394993     DOI: 10.1016/j.athoracsur.2017.09.035

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.

Authors:  Hiroaki Kodama; Tatsuya Ibe; Rentaro Inoue; Tetsuya Shimada; Hisashi Ishii; Yoichiro Hamamoto
Journal:  Cancer Rep (Hoboken)       Date:  2020-08-11

2.  Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.

Authors:  Donglin Zhu; Dan Cao; Minghong Shen; Jinghuan Lv
Journal:  BMC Cancer       Date:  2021-02-18       Impact factor: 4.430

3.  Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta-analysis of current evidence.

Authors:  Hongtao Tie; Jun Luo; Rui Shi; Zhenhan Li; Dan Chen; Qingchen Wu
Journal:  Cancer Med       Date:  2020-12-10       Impact factor: 4.452

4.  Clinicopathologic Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer.

Authors:  Ying Liu; Yu-Ping Zhou; Mai Zhang; Li Li; Hu Liao; Lin Ma; Feng Lin; Yue-Yun Chen; Chun-Xi Fu; Ting-Ting Huang; You Lu; Yan Zhang
Journal:  J Oncol       Date:  2021-12-23       Impact factor: 4.375

5.  In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.

Authors:  Bregtje C M Hermans; Jules L Derks; Lisa M Hillen; Irene van der Baan; Esther C van den Broek; Jan H von der Thüsen; Robert-Jan van Suylen; Peggy N Atmodimedjo; T Dorine den Toom; Cecile Coumans-Stallinga; Wim Timens; Winand N M Dinjens; Hendrikus J Dubbink; Ernst-Jan M Speel; Anne-Marie C Dingemans
Journal:  Int J Cancer       Date:  2021-11-10       Impact factor: 7.316

6.  The CT delta-radiomics based machine learning approach in evaluating multiple primary lung adenocarcinoma.

Authors:  Yanqing Ma; Jie Li; Xiren Xu; Yang Zhang; Yi Lin
Journal:  BMC Cancer       Date:  2022-09-03       Impact factor: 4.638

Review 7.  [Diagnosis and Treatment for Multiple Primary Lung Cancer].

Authors:  Lijie Tan; Jun Yin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-03-20

8.  Prognostic Factors Analysis and Nomogram Construction of Dual Primary Lung Cancer: A Population Study.

Authors:  Cong-Kuan Song; Zi-Xin Guo; Xiao-Yan Shen; Yu-Jin Wang; Qing-Wen Wang; Dong-Hu Yu; Chen Chen; Xiao-Ping Liu; Jing-Yu Huang; Sheng Li; Weidong Hu
Journal:  Biomed Res Int       Date:  2020-02-19       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.